0
JAMA 100 Years Ago |

IDENTIFYING THE MANUFACTURER

JAMA. 2012;307(8):758. doi:10.1001/jama.2012.76.
Text Size: A A A
Published online

Extract

Last week we called attention to a new organization, composed of a number of the large pharmaceutical manufacturing companies, the National Association of Manufacturers of Medicinal Preparations. Here it is worth noting that at least one manufacturing company was unable to stomach this newest cabal in the pharmaceutical world and refused to join it—although its representative was present at its organization. As we then recorded, with sorrow, this association is apparently opposed to legislation in the interest of public health and safely whenever such legislation would result in decreased profits for the manufacturers. For instance, it opposes the law that would prohibit the making of exaggerated and misleading therapeutic claims; it opposes the law that would regulate the transportation of habit-forming drugs and it opposes a law requiring the weight of drugs, sold in package form, to be printed on the label. To all this we called attention last week. The National Association of Manufacturers of Medicinal Preparations also opposes a law that would compel the manufacturers of all medicinal preparations to put their own names on their own products. Those of our readers who remember an article published in THE JOURNAL a year and a half ago, entitled “Pharmaceutical Manufacturers and the Great American Fraud,” will realize at once why this association of pharmaceutical manufacturers is opposed to any law that would permit the public and particularly the medical profession, to know the class of trade some of its members cater to. It would naturally prove embarrassing, if not positively painful, if some of the members of this association should have to put their names on such of their products as “Nyal's Headache Wafer,” which were declared misbranded under the Food and Drugs Act; “Robusto,” the “true bracer for young men”; the pills that were sold by the Nutriola fraud; the “patent medicines” that were supplied to “Professor” Adkin of the notorious New York Institute of Physicians and Surgeons; “Cascarets,” which “work while you sleep,” or “Danderine,” which “grows hair and we can prove it.” Under the circumstances, then, it is not surprising to learn that the secretary of the National Association of Manufacturers of Medicinal Preparations characterized the bill which would permit the public to identify the manufacturer as “a foolish provision,” or that the president of this organization should look on the bill as one “that we can conscientiously oppose.” If one's sense of humor can stand the strain, this fact is worth noticing: The president of this new organization, who thus opposes a law that will throw light on the connection between pharmaceutical manufacturers and the “great American fraud,” was nominated for his position by a manufacturer who has long shouted from the house-tops that he made “no dope for quackery”! Verily, politics and the nostrum business make strange bed-fellows!

Topics

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

References

CME
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs